You are here
Novartis gets creative in pricing next-generation cancer therapy
NOVARTIS AG, set to beat Kite Pharma Inc to the finish line in one of the most promising new areas of cancer research, is examining how to price a revolutionary therapy patients will need to take just once.
The US Food and Drug Administration is likely to rule in early
- CALL +65 6388 3838
- EMAIL firstname.lastname@example.org